Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri
The Disease Control Division of the Malaysian Ministry of Health (MOH) recently held a discussion on the current state of influenza cases in the country. They have concluded that the antiviral Oseltamivir should be prescribed as soon as possible to the high-risk group to prevent the worsening of inf...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
Faculty of Pharmacy
2023
|
| Subjects: | |
| Online Access: | https://ir.uitm.edu.my/id/eprint/85996/1/85996.pdf https://ir.uitm.edu.my/id/eprint/85996/ https://pharmacy.uitm.edu.my/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1833078876845113344 |
|---|---|
| author | Mat Supri, Nur Nadrah |
| author_facet | Mat Supri, Nur Nadrah |
| author_sort | Mat Supri, Nur Nadrah |
| building | Tun Abdul Razak Library |
| collection | Institutional Repository |
| content_provider | Universiti Teknologi Mara |
| content_source | UiTM Institutional Repository |
| continent | Asia |
| country | Malaysia |
| description | The Disease Control Division of the Malaysian Ministry of Health (MOH) recently held a discussion on the current state of influenza cases in the country. They have concluded that the antiviral Oseltamivir should be prescribed as soon as possible to the high-risk group to prevent the worsening of influenza-like illness (ILI) and to reduce hospitalization. The high-risk populations that should be thoroughly evaluated and considered to be prescribed with Oseltamivir include: 1. individuals with chronic respiratory diseases including asthma, chronic obstructive pulmonary disorder (COPD), and obstructive sleep apnea 2. pregnant women or 2 weeks post-natal women (Pregnancy category: C) 3. obese individuals with body mass index (BMI) of more than 40 4. individuals with comorbidities or chronic illnesses such as chronic heart diseases, diabetes mellitus, chronic kidney diseases and blood disorders 5. individuals with weak immune system including cancer, HIV/AIDS, undergoing chemotherapy/on long-term steroids or organ transplantation 6. geriatric patients of more than 65 years of age with chronic illnesses 7. paediatric patients of less than 6 months of age 80 paediatric patients with comorbidities/chronic illnesses |
| format | Article |
| id | my.uitm.ir-85996 |
| institution | Universiti Teknologi Mara |
| language | en |
| publishDate | 2023 |
| publisher | Faculty of Pharmacy |
| record_format | eprints |
| spelling | my.uitm.ir-859962023-11-02T08:24:54Z https://ir.uitm.edu.my/id/eprint/85996/ Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri Mat Supri, Nur Nadrah RC Internal Medicine Vaccinotherapy. Vaccines The Disease Control Division of the Malaysian Ministry of Health (MOH) recently held a discussion on the current state of influenza cases in the country. They have concluded that the antiviral Oseltamivir should be prescribed as soon as possible to the high-risk group to prevent the worsening of influenza-like illness (ILI) and to reduce hospitalization. The high-risk populations that should be thoroughly evaluated and considered to be prescribed with Oseltamivir include: 1. individuals with chronic respiratory diseases including asthma, chronic obstructive pulmonary disorder (COPD), and obstructive sleep apnea 2. pregnant women or 2 weeks post-natal women (Pregnancy category: C) 3. obese individuals with body mass index (BMI) of more than 40 4. individuals with comorbidities or chronic illnesses such as chronic heart diseases, diabetes mellitus, chronic kidney diseases and blood disorders 5. individuals with weak immune system including cancer, HIV/AIDS, undergoing chemotherapy/on long-term steroids or organ transplantation 6. geriatric patients of more than 65 years of age with chronic illnesses 7. paediatric patients of less than 6 months of age 80 paediatric patients with comorbidities/chronic illnesses Faculty of Pharmacy 2023-09 Article PeerReviewed text en https://ir.uitm.edu.my/id/eprint/85996/1/85996.pdf Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri. (2023) Prescription <https://ir.uitm.edu.my/view/publication/Prescription/> (9): 16. pp. 1-4. https://pharmacy.uitm.edu.my/ |
| spellingShingle | RC Internal Medicine Vaccinotherapy. Vaccines Mat Supri, Nur Nadrah Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title | Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title_full | Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title_fullStr | Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title_full_unstemmed | Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title_short | Influenza antiviral: Oseltamivir / Nur Nadrah Mat Supri |
| title_sort | influenza antiviral: oseltamivir / nur nadrah mat supri |
| topic | RC Internal Medicine Vaccinotherapy. Vaccines |
| url | https://ir.uitm.edu.my/id/eprint/85996/1/85996.pdf https://ir.uitm.edu.my/id/eprint/85996/ https://pharmacy.uitm.edu.my/ |
| url_provider | http://ir.uitm.edu.my/ |